LEXICON PHARMACEUTICALS, INC. — Director's Dealing 2018

Jun 7, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK: 0001062822
Period of Report: 2018-06-05

Reporting Person: Invus Public Equities, L.P. (Director, 10% Owner)
Reporting Person: Artal International S.C.A. (Director, 10% Owner)
Reporting Person: Artal International Management S.A. (Director, 10% Owner)
Reporting Person: Artal Group S.A. (Director, 10% Owner)
Reporting Person: Westend S.A. (Director, 10% Owner)
Reporting Person: Stichting Administratiekantoor Westend (Director, 10% Owner)
Reporting Person: Minne Pascal (Director, 10% Owner)
Reporting Person: Invus, L.P. (Director, 10% Owner)
Reporting Person: Invus Advisors, L.L.C. (Director, 10% Owner)
Reporting Person: Invus Public Equities Advisors, LLC (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-05	Common Stock	P	173121	$12.4548	Acquired	2572980	Indirect
2018-06-06	Common Stock	P	95079	$12.5829	Acquired	2668059	Indirect
2018-06-07	Common Stock	P	57439	$12.9269	Acquired	2725498	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	21321961	Indirect
Common Stock	35402689	Indirect

Footnotes

F1: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2: The shares reported as purchased on June 5, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.10 to $12.73 per share, the shares reported as purchased on June 6, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.32 to $12.76 per share, and the shares reported as purchased on June 7, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.61 to $13.06 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3: These securities are directly held by Invus Public Equities, L.P.

F4: These securities are directly held by Artal International S.C.A.

F5: These securities are directly held by Invus, L.P.

F6: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.